Credit Suisse analyst Judah Frommer raised the firm’s price target on PTC Therapeutics to $51 from $48 and keeps a Neutral rating on the shares following the Q1 earnings report. Management’s Q&A focused on the four upcoming readouts in Q2, which will inform a future portfolio review and possible OpEx reduction, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PTCT:
- William Blair healthcare analysts to hold an analyst/industry conference call
- PTC Therapeutics reports Q1 EPS ($1.88), consensus ($1.39)
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- PTC Therapeutics participates in a conference call with JPMorgan
- Is PTCT a Buy, Before Earnings?
